Federico Longo

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

Sebastián Morán, Anna Martínez‐Cardús, Sergi Sayols et al. · The Lancet Oncology · 2016 · 497 citations

Oncology, Tumor Heterogeneity, Unknown Primary +13

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

Michele Maio, Paolo A. Ascierto, L. V. Manzyuk et al. · Annals of Oncology · 2022 · 404 citations · Full text

Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

Shubham Pant, Martin Schüler, Gopa Iyer et al. · The Lancet Oncology · 2023 · 175 citations · Full text

Fgfr Alterations, Medicine, Pathology +7

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors

Iván Márquez‐Rodas, Federico Longo, María E. Rodríguez-Ruiz et al. · Science Translational Medicine · 2020 · 80 citations

SEOM clinical guideline on unknown primary cancer (2017)

Ferrán Losa, G. Soler, Antonio Casado et al. · Clinical & Translational Oncology · 2017 · 69 citations · Full text